Pre-publication history
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
-
* Corresponding author: H Lubenau heinz.lubenau@t-online.de
BMC Cancer 2008, 8:332 doi:10.1186/1471-2407-8-332
Pre-publication versions of this article and reviewers' reports
| Original Submission - Version 1 | Manuscript | 28 Apr 2008 | |
| Resubmission - Version 2 | Manuscript | Author's comment | 02 Jun 2008 |
| Reviewer's Report | Christian Chabannon | 09 Jul 2008 | |
| Reviewer's Report | Vassilis Georgoulias | 24 Jul 2008 | |
| Resubmission - Version 3 | Manuscript | 01 Oct 2008 | |
| Reviewer's Report | Christian Chabannon | 22 Oct 2008 | |
| Reviewer's Report | Vassilis Georgoulias | 03 Nov 2008 | |
| Editorial acceptance | 06 Nov 2008 | ||
| Published | 12 Nov 2008 |